SkinDermic® is a drug discovery company focused on developing breakthrough and innovative small molecule drugs for the treatment of HHV8 virus linked neoplasia and inflammatory skin diseases.
SkinDermic® recently completed proof of concept clinical phase in humans with its First-in-Class treatments for acne and HHV8 associated diseases (Kaposi Sarcoma and Lymphomas).
Skindermic owns now a pipeline with very active and very well tolerated new drugs for HHV8 associated diseases and acne vulgaris.
Company Details
- Employees
- 5
- Founded
- 2017
- Address
- Paris, Île-De-France
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- skindermic.com
- HQ
- Paris, Île-de-France
Skindermic Questions
Skindermic's website is skindermic.com
Skindermic's LinkedIn profile is https://fr.linkedin.com/company/skindermic
Skindermic has
5 employees.
View email and phone details for 5
employees at Skindermic.
Skindermic's industry is
Biotechnology Research
Skindermic's top competitors are
Icanc,
Chemjiva,
Dermatologist And Aesthetics,
Charles University Faculty Of Medicine In Pilsen,
Running With Fire 🔥 Ministries Npc,
Dérmica Medesthetics,
Iberocel,
Skinderms,
Cliniem,
Century 21 Galaxy.
Skindermic's categories are Biotechnology Research
Skindermic's founding year is 2017
